Crossject

Supergenerics / France





Fabrice FARIGOULE pharma@alphavalue.eu +33 (0) 1 70 61 10 50 corporate.alphavalue.com

AlphaValue is contracted by Crossject to provide equity research on Crossject , using AlphaValue's unique and transparent methods and procedures. Target price and opinion are thus exclusively determined by those methods and procedures.

Buy	Upside: 268%
Target Price (6 months)	€ 19.3
Share Price	€ 5.24
Market Capitalisation €M	34.9
Price Momentum	UNFAVORABLE
Extremes 12Months	4.46 🕨 11.1
Bloomberg	ALCJ FP Equity
Reuters	ALCJ.PA

Download Full Analysis Company Page



PERF	1 w	1m	3	m	12m
Crossject	1.35%	-4.90%	6 13	.2% -	38.7%
Pharma	-0.82%	6.45%	5 11	.6% [~]	11.6%
STOXX 600	-0.53%	2.55%	5.0	2% [·]	11.9%
Last updated: 2	4/11/2016	12/14A	12/15A	12/16E	12/17E
Adjusted P/E (x)		-14.0	-8.17	-8.80	-10.5
Dividend yield (%	.)	0.00	0.00	0.00	0.00
EV/EBITDA(R) (x)	-12.7	-7.63	-9.04	-15.7
Adjusted EPS (€)		-0.68	-0.88	-0.90	-0.50
Growth in EPS (%	%)	n/a	n/a	n/a	n/a
Dividend (€)		0.00	0.00	0.00	0.00
Sales (€M)		1.74	2.37	2.37	2.00
EBITA margin (%)	ns	ns	ns	-87.1
Attributable net p	rofit (€M)	-4.44	-5.73	-5.80	-3.24
ROE (after tax) (%)	-30.6	-49.2	-98.5	-236
Gearing (%)			-91.3	-190	
0			0		

Company Valuation - Company Financials

FY16 results - untelling (as expected) and a €4.3m capital increase

Earnings/sales releases - 11/03/2017

Fact

Crossject released its FY16 results. Revenues reached €1.43m vs €2.73m in FY15 (-48%), operating result €-7,291k (vs €-7,013k), and the net result €-6,663k (vs €-5,687k). Net cash at the end of FY16 amounted to €2.6m (vs €5.2m a year before). The company also announced a capital increase (€4.3m at €4.5 per share with subscription rights), which is 75% underwritten by the main shareholder, Gemmes Ventures.

Analysis

The numbers as such are irrelevant, as we previously mentioned, since the story of Crossject is based on the future launch of Zeneo combined with the NTEs the group is targeting. However, we note that the net loss is above our expectation (\in -5.8m) on slightly lower revenues and despite rather high operating expenses which are kept under control. The net cash position has significantly decreased (capex of \in 6m, while our forecasts also included some milestone payments on Zeneo Adrenaline which hasn't occurred yet).


As a reminder, Crossject has decided to review its strategy, particularly by insisting first on emergency NTEs among its current portfolio of seven NTEs, and more specifically on the products that could lead to early distribution agreements (with upfront fees) in the US and could get market approvals through a "fast-track" procedure (see our comment dated 23 November 2016, with, at that time, the delay in expected product launches vs the group's initial plans).

As a result, Crossject is launching a capital increase, issuing a maximum number of 963k shares (before a potential 15% extension clause, thus a maximum of 1,107k shares) at a price of \leq 4.50 per share. Eight subscription rights will entitle holders to acquire one share. The subscription period will run from 16-30 March. Gemmes Ventures, Crossject's main shareholder with c.20%, has committed itself to taking part in the capital increase and is also underwriting the issue, up to 75% of the shares to be issued. At the end of the day, and considering 963k shares will be issued, this will increase the total number of shares from 7.7m to 8.6m.

Impact

We will fine-tune our numbers, mainly due to the capital increase and the dilution stemming from it. However, it is worth mentioning that the move secures the group's financing, while it is expecting cash inflows (refundable incentives, milestone payments) to fund future developments.

Sales by Geography



Consolidated P&L Accounts		12/15A	12/16E	12/17E
Sales	€M	2.37	2.37	2.00
Change in sales	%	35.8	0.00	-15.6
Change in staff costs	%	32.0	15.9	63.2
EBITDA	€M	-5.51	-5.00	-1.74
EBITDA(R) margin	%	-232	-211	-87.1
Depreciation	€M	-1.51	-1.51	-1.20
Underlying operating profit	€M	-7.01	-6.50	-2.94
Operating profit (EBIT)	€M	-7.06	-6.50	-2.94
Net financial expense	€M	0.29	-0.30	-0.30
of which related to pensions	€M		0.00	0.00
Exceptional items & other	€M	-0.01	0.00	0.00
Corporate tax	€M	1.05	1.00	0.00
Equity associates	€M			
Minority interests	€M			
Adjusted attributable net profit	€M	-5.73	-5.80	-3.24
NOPAT	€M	-4.91	-4.55	-2.06
Cashflow Statement				
EBITDA	€M	-5.51	-5.00	-1.74
Change in WCR	€M	-0.41	0.92	0.09
Actual div. received from equity holdi	€M	0.00	0.00	0.00
Paid taxes	€M	1.00	1.00	0.00
Exceptional items	€M	0.00	0.00	0.00
Other operating cash flows	€M	0.00	0.00	0.00
Total operating cash flows	€M	-4.91	-3.07	-1.6
Capital expenditure	€M	-1.81	-7.50	-0.50
Total investment flows	€M	-1.81	-7.50	-0.50
Net interest expense	€M	0.29	-0.30	-0.30
Dividends (parent company)	€M			
Dividends to minorities interests	€M	0.00	0.00	0.00
New shareholders' equity	€M	0.00	0.00	0.00
Total financial flows	€M	1.12	11.7	12.8
Change in cash position	€M	-5.60	1.11	10.6
Free cash flow (pre div.)	€M	-6.43	-10.9	-2.45
Per Share Data				
No. of shares net of treas. stock (year	Mio	6.48	6.48	6.48
Number of diluted shares (average)	Mio	6.48	6.48	6.48
Benchmark EPS	€	-0.88	-0.90	-0.50
Restated NAV per share	€			
Net dividend per share	€	0.00	0.00	0.00

Valuation Summary

Benchmarks	Value	Weight
DCF	€23.0	40%
NAV/SOTP per share	€24.5	40%
P/E	€ 2.62	5%
EV/Ebitda	€ 0.00	5%
P/Book	€ 2.62	5%
Dividend Yield	€ 0.00	5%
TARGET PRICE	€ 19.3	100%

Largest comparables

- Actelion
- Faes Farma
 Hikma Pharmaceuti...
- IpsenStada Arzneimittel
- UCB

NAV/SOTP Calculation

Balance Sheet		12/15A	12/16E	12/17E
Goodwill	€M	0.00	0.00	0.00
Total intangible	€M	2.33	8.33	7.79
Tangible fixed assets	€M	1.74	1.73	1.57
Financial fixed assets	€M	1.85	1.85	1.85
WCR	€M	-2.50	-3.42	-3.52
Other assets	€M	2.04	2.04	2.04
Total assets (net of short term liab.)	€M	5.48	10.5	9.76
Ordinary shareholders' equity	€M	8.80	2.99	-0.25
Quasi Equity & Preferred	€M			
Minority interests	€M			
Provisions for pensions	€M	0.00	0.00	0.00
Other provisions for risks and liabilities	€M	0.34	0.34	0.34
Total provisions for risks and liabilities	€M	0.34	0.34	0.34
Tax liabilities	€M	0.00	0.00	0.00
Other liabilities	€M	1.48	13.5	16.6
Net debt (cash)	€M	-5.14	-6.24	-6.89
Total liab. and shareholders' equity	€M	5.48	10.5	9.76
Capital Employed				
Capital employed after depreciation	€M	3.42	8.49	7.70
Profits & Risks Ratios				
ROE (after tax)	%	-49.2	-98.5	-236
ROCE	%	-143	-53.6	-26.7
Gearing (at book value)	%	-91.3	-190	
Adj. Net debt/EBITDA(R)	Х	0.93	1.25	3.96
Interest cover (x)	Х	24.0	-21.7	-9.80
Valuation Ratios				
Reference P/E (benchmark)	x	-8.17	-8.80	-10.5
Free cash flow yield	%	-13.7	-21.3	-7.22
P/Book	х	5.32	17.1	-137
Dividend yield	%	0.00	0.00	0.00
EV Calculation				
Market cap	€M	46.8	51.1	34.0
+ Provisions	€M	0.34	0.34	0.34
	€M	0.00	0.00	0.00
+ Unrecognised acturial losses/(gains)		-5.14	-6.24	-6.89
+ Unrecognised acturial losses/(gains) + Net debt at year end	€M			
	€M €M	0.00	0.00	0.00
+ Net debt at year end				0.00
+ Net debt at year end + Leases debt equivalent	€M			0.00
+ Net debt at year end + Leases debt equivalent - Financial fixed assets (fair value)	€M €M			0.00 27.4
 + Net debt at year end + Leases debt equivalent - Financial fixed assets (fair value) + Minority interests (fair value) 	€M €M €M	0.00	0.00	

Analyst : Fabrice Farigoule, Changes to Forecasts : 24/11/2016.

© 2017. AlphaValue All rights reserved. Contract research, paid for by the above corporate entity. Equity research methods and procedures are as applied by AlphaValue. Target prices and opinions are thus exclusively determined by those methods and procedures. All opinions and estimates included herein represent the personal, technical judgment of the analyst as of the date of this report and are subject to change without prior notice. The information contained herein has been compiled from sources believed to be reliable, but while all reasonable care has been taken to ensure that the information contained herein is not untrue or misleading at the time of publication, we make no representation that it is accurate or compiled and it should not be relied upon as such. AlphaValue does not accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents, including the investment view held in this report.